S-Citalopram in neuroendocrine challenge-tests: Serotonergic responsivity in healthy male and female human participants

Psychoneuroendocrinology

Volumn 31, Issue 10, 2006, Pages 1200-1207

  Kuepper, Yvonne ^a   Bausch, Sandra ^a   Iffland, Jona ^a   Reuter, Martin ^b   Hennig, Juergen ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

5 HT; Challenge test; Cortisol; S Citalopram; Serotonin

Indexed keywords

CITALOPRAM;

ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DYSGEUSIA; FEMALE; HEADACHE; HUMAN; INDIGESTION; MALE; MENSTRUAL CYCLE; NAUSEA; NEUROENDOCRINE SYSTEM; NORMAL HUMAN; PRIORITY JOURNAL; PROVOCATION TEST; PRURITUS; SEROTONINERGIC SYSTEM; SEX RATIO; SHIVERING; SIDE EFFECT; SOMNOLENCE; SWEATING; VISUAL ANALOG SCALE; VISUAL IMPAIRMENT;

ADULT; CITALOPRAM; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCORTISONE; MALE; PLACEBOS; SALIVA; SEROTONIN UPTAKE INHIBITORS;

EID: 33751203250     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2006.09.001     Document Type: Article

References (59)

1. Amin Z., Canli T., and Epperson C.N. Effect of estrogen-serotonin interactions on mood and cognition. Beh. Cogn. Neurosci. Rev. 4 (2005) 43-58
2. Arato M., and Bagdy G. Gender difference in m-CPP challenge test in healthy volunteers. Int. J. Neuropsychopharmcol. 1 (1998) 121-124
3. Attenburrow M.J., Mitter P.R., Whale R., Terao T., and Cowen P.J. Low-dose citalopram as a 5-HT neuroendocrine probe. Psychopharmacology 155 (2001) 323-326
4. Bethea C.L., Lu N.Z., Gundlah C., and Streicher J.M. Diverse actions of ovarian steroids in the serotonin neural system. Front. Neuroendocrinol. 23 (2002) 41-100
5. Bhagwagar Z., Hafizi S., and Cowen P.J. Acute citalopram administration produces correlated increases in plasma and salivary cortisol. Psychopharmacology 163 (2002) 118-120
6. Bhagwagar Z., Whale R., and Cowen P.J. State and trait abnormalities in serotonin function in major depression. Brit. J. Psychiat. 180 (2002) 24-28
7. Biver F., Lotstra F., Monclus M., Wikler D., Damhaut P., Mendlewicz J., and Goldman S. Sex difference in 5HT2 receptor in the living human brain. Neurosci. Lett. 204 (1996) 25-28
8. Burke W.J. Escitalopram. Expert. Opin. Investig. Drugs 11 (2002) 1477-1486
9. Burke W.J., and Kratochvil C.J. Stereoisomers in psychiatry: the case of Escitalopram. Prim. Care Companion J. Clin. Psychiatry 4 (2002) 20-24
10. Culpepper L. Escitalopram: a new SSRI for the treatment of depression in primary care. Prim. Care Companion J. Clin. Psychiatry 4 (2002) 209-214
11. Ellenbogen M.A., Young S.N., Dean P., Palmour R.M., and Benkelfat C. Mood response to acute tryptophan depletion in healthy volunteers: sex differences and temporal stability. Neuropsychopharmacology 15 (1996) 465-474
12. Flory J.D., Manuck S.B., Perel J.M., and Muldoon M.F. A comparison of d,l-fenfluramine and citalopram challenges in healthy adults. Psychopharmacology 174 (2004) 376-380
13. Garattini S., Mennini T., and Samanin R.. From fenfluramine racemate to d-fenfluramine. Specificity and potency of the effects on the serotoninergic system and food intake. Ann. N.Y. Acad. Sci. 499 (1987) 156-166
14. Golden R.N., Gilmore J.H., Ekstrom R.D., Knight B., Ruegg R.G., Miller H.L., and Carson S.W. The effects of age, gender, and season on serotonergic function in healthy subjects. Prog. Neuropsychopharmacol. Biol. Psychiatry 20 8 (1996) 1315-1323
15. Halbreich U., Rojansky N., Palter S., Tworek H., Hissin P., and Wang K. Estrogen augments serotonergic activity in postmenopausal women. Biol. Psychiatry 37 7 (1995) 434-441
16. Hennig J., and Netter P. Oral application of citalopram (20 mg) and its usefulness for neuroendocrine challenge tests. Int. J. Neuropsychopharmacol. 5 (2002) 67-71
17. Hogg S., and Sánchez C. The antidepressant effects of citalopram are mediated by the S-(+)- and not the R-(-)-enantiomer. Eur. Neuropsychopharmacol. 9 s5 (1999) 213
18. Hyttel J., Bogeso K.P., Perregaard J., and Sanchez C. The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J. Neural Transm. Gen. Sect. 88 (1992) 157-160
19. Invernizzi R., Berettera C., Garattini S., and Samanin R. d- and l-isomers of fenfluramine differ markedly in their interaction with brain serotonin and catecholamines in the rat. Eur. J. Pharmacol. 120 (1986) 9-15
20. Kapitany T., Schindl M., Schindler S.D., Hesselmann B., Fureder T., Barnas C., Sieghart W., and Kasper S. The citalopram challenge test in patients with major depression and in healthy controls. Psychiatry Res. 88 (1999) 75-88
21. Kirschbaum C., and Hellhammer D.H. Salivary cortisol in psychoneuroendocrine research: Recent developments and applications. Psychoneuroendocrinology 19 (1994) 313-333
22. Kugaya A., Epperson C.N., Zoghbi S., van Dyck C.H., Hou Y., Fujita M., Staley J.K., Garg P.K., Seibyl J.P., and Innis R.B. Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. Am. J. Psychiatry 160 (2003) 1522-1524
23. Laakmann G., Gugath M., Kuss H.J., and Zygan K. Comparison of growth hormone and prolactin stimulation induced by chlorimipramine and desimipramine in man in connection with chlorimipramine metabolism. Psychopharmacology 82 (1984) 62-67
24. Lerer B., Gillon D., Lichtenberg P., Gorfine M., Gelfin Y., and Shapira B. Interrelationship of age, depression, and central serotonergic function: evidence from fenfluramine challenge studies. Int. Psychogeriatr. 8 1 (1996) 83-102
25. Lotrich F.E., Bies R., Muldoon M.F., Manuck S.B., Smith G.S., and Pollock B.G. Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences. Psychopharmacology 178 (2005) 268-275
26. Lucki I. The spectrum of behaviors influenced by serotonin. Biol. Psychiatry 44 (1998) 151-162
27. Lucki I., and Brown K. Diffrent roles of the enantiomers of citalopram on serotonin transmission. Biol. Psychiatry 53 (2003) 45S
28. Maskall D.D., Zis A.P., Lam R.W., Clark C.M., and Kuan A.J. Prolactin response to buspirone challenge in the presence of dopaminergic blockade. Biol. Psychiatry 38 (1995) 235-239
29. McBride P.A., Tierney H., DeMeo M., Chen J.S., and Mann J.J. Effects of age and gender on CNS serotonergic responsivity in normal adults. Biol. Psychiatry 27 10 (1990) 1143-1155
30. McEwen B.S. Invited review: estrogens effects on the brain: multiple sites and molecular mechanisms. J. Appl. Physiol. 91 (2001) 2785-2801
31. McEwen B. Estrogen actions throughout the brain. Recent Prog. Horm. Res. 57 (2002) 357-384
32. Millan M.J., Dekeyne A., Papp M., La Rochelle C.D., MacSweeny C., Peglion J.L., and Brocco M. S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J. Pharmacol. Exp. Ther. 298 (2001) 581-591
33. Mork A., Kreilgaard M., and Sanchez C. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 45 (2003) 167-173
34. Monteleone P., Catapano F., Tortorella A., and Maj M. Cortisol response to d-fenfluramine in patients with obsessive-compulsive disorder and in healthy subjects: evidence for a gender-related effect. Neuropsychobiology 36 1 (1997) 8-12
35. Muldoon M.F., Manuck S.B., Jansma C.L., Moore A.L., Perel J., and Mann J.J. D,L-fenfluramine challenge test: experience in nonpatient sample. Biol. Psychiatry 39 9 (1996) 761-768
36. Mundo E., Bareggi S.R., Pirola R., and Bellodi L. Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable?. Biol. Psychiatry 45 3 (1999) 290-294
37. Nadeem H.S., Attenburrow M.J., and Cowen P.J. Comparison of the effects of citalopram and escitalopram on 5-Ht-mediated neuroendocrine responses. Neuropsychopharmacology 29 (2004) 1699-1703
38. O'Keane V., O'Hanlon M., Webb M., and Dinan T. d-fenfluramine/prolactin response throughout the menstrual cycle: evidence for an oestrogen-induced alteration. Clin. Endocrinol. 34 (1991) 289-292
39. Owens M.J., Knight D.L., and Nemeroff C.B. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry 50 (2001) 345-350
40. Parsey, R.V., Oquendo, M.A., Simpson, N.R., Ogden, R.T., Van, H.R., Arango, V., Mann, J.J., 2002. Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT1A receptor binding potential measured by PET using [C-11]WAY-100635. Brain.
41. Rothman R.B., and Baumann M.H. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol. Ther. 95 (2002) 73-88
42. Rothman R.B., Clark R.D., Partilla J.S., and Baumann M.H. (+)-Fenfluramine and its major metabolite, (+)-norfenfluramine, are potent substrates for norepinephrine transporters. J. Pharmacol. Exp. Ther. 305 (2003) 1191-1199
43. Rubinow D.R., Schmidt P.J., and Roca C.A. Estrogen-serotonin interactions: implications for affective regulation. Biol. Psychiatry 44 (1998) 839-850
44. Sallee F.R., Vrindavanam N.S., Deas-Nesmith D., Odom A.M., Carson S.W., and Sethuraman G. Parenteral clomipramine challenge in depressed adolescents: mood and neuroendocrine response. Biol. Psychiatry. 44 7 (1998) 562-567
45. Sanchez C., Bergqvist P.B., Brennum L.T., Gupta S., Hogg S., Larsen A., and Wiborg O. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology 167 (2003) 353-362
46. Sanchez C., Bogeso K.P., Ebert B., Reines E.H., and Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology 174 (2004) 163-176
47. Sanchez C., and Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell. Mol. Neurobiol. 19 (1999) 467-489
48. Sanchez C., and Kreilgaard M. R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol. Biochem. Behav. 77 (2004) 391-398
49. Seifritz E., Baumann P., Muller M.J., Annen O., Amey M., Hemmeter U., Hatzinger M., Chardon F., and Holsboer-Trachsler E. Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology 14 (1996) 253-263
50. Sogaard B., Mengel H., Rao N., and Larsen F. The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J. Clin. Pharmacol. 45 (2005) 1400-1406
51. Stahl S.M., Gergel I., and Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 64 (2003) 1322-1327
52. Storlien L.H., and Smythe G.A. D-fenfluramine effects on hypothalamic monoamine activities and their hormonal correlates. Brain Res. 597 (1992) 60-65
53. Storustovu S., Sanchez C., Porzgen P., Brennum L.T., Larsen A.K., Pulis M., and Ebert B. R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. Br. J. Pharmacol. 142 (2004) 172-180
54. Sullivan P.W., Valuck R., Saseen J., and MacFall H.M. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 18 (2004) 911-932
55. Uphouse L. Female gonadal hormones, serotonin, and sexual receptivity. Brain Res. Brain Res. Brain Res. Rev. 33 (2000) 242-257
56. van Praag H.M., Lemus C., and Kahn R. Hormonal probes of central serotonergic activity: do they really exist?. Biol. Psychiatry 22 (1987) 86-98
57. Vanderhorst V.G., Gustafsson J.A., and Ulfhake B. Estrogen receptor-alpha and -beta immunoreactive neurons in the brainstem and spinal cord of male and female mice: relationships to monoaminergic, cholinergic, and spinal projection systems. J. Comp. Neurol. 488 (2005) 152-179
58. von Moltke L.L., Greenblatt D.J., Giancarlo G.M., Granda B.W., Harmatz J.S., and Shader R.I. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab. Dispos. 29 (2001) 1102-1109
59. Zarate A., Fonseca E., Ochoa R., Basurto L., and Hernandez M. Low-dose conjugated equine estrogens elevate circulating neurotransmitters and improve the psychological well-being of menopausal women. Fertil. Steril. 77 (2002) 952-955